KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBIT Margin (2018 - 2025)

Adaptive Biotechnologies' EBIT Margin history spans 8 years, with the latest figure at 17.82% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 5348.0% year-over-year to 17.82%; the TTM value through Dec 2025 reached 20.62%, up 7021.0%, while the annual FY2025 figure was 20.62%, 7021.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 17.82% at Adaptive Biotechnologies, down from 10.95% in the prior quarter.
  • Across five years, EBIT Margin topped out at 10.95% in Q3 2025 and bottomed at 621.01% in Q2 2023.
  • The 5-year median for EBIT Margin is 113.0% (2024), against an average of 126.36%.
  • The largest annual shift saw EBIT Margin plummeted -50076bps in 2023 before it surged 51146bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 162.39% in 2021, then soared by 56bps to 70.99% in 2022, then plummeted by -119bps to 155.22% in 2023, then skyrocketed by 54bps to 71.3% in 2024, then surged by 75bps to 17.82% in 2025.
  • Per Business Quant, the three most recent readings for ADPT's EBIT Margin are 17.82% (Q4 2025), 10.95% (Q3 2025), and 42.52% (Q2 2025).